Historical record - last NADAC effective date: 9/18/2024
Product Information
TRI FEMYNOR 28 TABLET is a generic product labeled by Amneal Pharmaceuticals NY LLC, priced at $0.1346 per EA under NDC 69238160706. Its NADAC has been published 371 times since Aug 30, 2017.
FDA first approved this application on Nov 12, 2015.
The High Outlier badge above means this manufacturer's average price in the norgestimate and ethinyl estradiol market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Amneal Pharmaceuticals NY LLCNDC
69238160706
Classification
Generic
Dosage Form
KIT
Effective Date
9/18/2024
Approval Type
Generic (ANDA)
FDA Application
ANDA203870FDA Approved
11/12/2015
On Market Since
10/28/2016
Price Statistics
The NADAC for TRI FEMYNOR 28 TABLET has been published 371 times since Aug 30, 2017, and over the history we have for it it has declined 48.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1346 per EA |
|---|---|
| All-time high | $0.2726 (Oct 11, 2017) |
| All-time low | $0.1072 (Jul 17, 2024) |
| Median price | $0.1832 |
| Average price | $0.1808 |
| Largest weekly change | -19.9% (Jul 17, 2024) |
| Weeks tracked | 371 |
| Tracking since | Aug 30, 2017 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-4.8%
5Y
-22.0%
All
-48.1%
Last surveyed Oct 2, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 20% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amneal Pharmaceuticals NY LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norgestimate and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRI FEMYNOR 28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI FEMYNOR 28 TABLET, manufactured by Amneal Pharmaceuticals NY LLC, is $0.1346 per EA (NDC 69238160706), effective Oct 2, 2024.
How has the price of TRI FEMYNOR 28 TABLET changed over time?
Over the history we have for it, the NADAC for TRI FEMYNOR 28 TABLET has declined 48.1%. It has been tracked across 371 weekly CMS publications since Aug 30, 2017.
What are the highest and lowest recorded NADAC prices for TRI FEMYNOR 28 TABLET?
Since Aug 30, 2017, the NADAC for TRI FEMYNOR 28 TABLET has ranged from a low of $0.1072 (Jul 17, 2024) to a high of $0.2726 (Oct 11, 2017), with a median of $0.1832 per EA.
Are there cheaper alternatives to TRI FEMYNOR 28 TABLET?
Yes. 8 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRI-LO-ESTARYLLA TABLET, is $0.1080 per EA — about 20% below TRI FEMYNOR 28 TABLET.
Who manufactures TRI FEMYNOR 28 TABLET?
TRI FEMYNOR 28 TABLET (NDC 69238160706) is labeled by Amneal Pharmaceuticals NY LLC, and CMS classifies it as a generic product.